Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

A. Spencer, S. Lentzsch, K. Weisel, H. Avet-Loiseau, TM. Mark, I. Spicka, T. Masszi, B. Lauri, MD. Levin, A. Bosi, V. Hungria, M. Cavo, JJ. Lee, AK. Nooka, H. Quach, C. Lee, W. Barreto, P. Corradini, CK. Min, EC. Scott, AA. Chanan-Khan, N....

. 2018 ; 103 (12) : 2079-2087. [pub] 20180920

Jazyk angličtina Země Itálie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19045233

Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or refractory multiple myeloma. A post hoc analysis based on treatment history and longer follow up is presented. After 19.4 (range: 0-27.7) months of median follow up, daratumumab plus bortezomib and dexamethasone prolonged progression-free survival (median: 16.7 versus 7.1 months; hazard ratio, 0.31; 95% confidence interval, 0.24-0.39; P<0.0001) and improved the overall response rate (83.8% versus 63.2%; P<0.0001) compared with bortezomib and dexamethasone alone. The progression-free survival benefit of daratumumab plus bortezomib and dexamethasone was most apparent in patients with 1 prior line of therapy (median: not reached versus 7.9 months; hazard ratio, 0.19; 95% con fidence interval, 0.12-0.29; P<0.0001). Daratumumab plus bortezomib and dexamethasone was also superior to bortezomib and dexamethasone alone in subgroups based on prior treatment exposure (bortezomib, thalidomide, or lenalidomide), lenalidomide-refractory status, time since last therapy (≤12, >12, ≤6, or >6 months), or cytogenetic risk. Minimal residual disease-negative rates were >2.5-fold higher with daratumumab across subgroups. The safety profile of daratumumab plus bortezomib and dexamethasone remained consistent with longer follow up. Daratumumab plus bortezomib and dexamethasone demonstrated significant clinical activity across clinically relevant subgroups and provided the greatest benefit to patients treated at first relapse. Trial registration: clinicaltrials.gov identifier: 02136134.

Albert Schweitzer Hospital Department of Internal Medicine Dordrecht the Netherlands

Ankara University Turkey

Clinical Department of Haematology 1 Medical Department Charles University Prague Czech Republic

Department of Haematology and Stem Cell Transplantation St László Hospital 3 Department of Internal Medicine Semmelweis University Budapest Hungary

Department of Hematology Careggi Hospital and University of Florence Italy

Department of Hematology Oncology Chonnam National University Hwasun Hospital Jeollanamdo South Korea

Department of Hematology Sunderbyn Hospital Luleå Sweden

Department of Medicine University of Colorado Aurora CO USA

Division of Hematology Oncology Columbia University New York NY USA

Division of Hematology Oncology Department of Internal Medicine School of Medicine Medical Research Institute Pusan National University Hospital Busan South Korea

Erasmus Medical Center Rotterdam the Netherlands

Fondazione IRCCS Instituto Nazionale dei Tumori University of Milan Italy

Genmab US Inc Princeton NJ USA

Hospital Angeles Lomas Naucalpan de Juárez y alrededores México

Hospital Santa Marcelina São Paulo Brazil

Instituto do Cancer Hospital Mae de Deus Porto Alegre Brazil

Irmandade Da Santa Casa De Misericordia De São Paulo Brazil

Janssen Research and Development Beerse Belgium

Janssen Research and Development High Wycombe UK

Janssen Research and Development LLC Raritan NJ USA

Janssen Research and Development LLC Spring House PA USA

Malignant Haematology and Stem Cell Transplantation Service Alfred Health Monash University Melbourne Australia

Mayo Clinic Florida Jacksonville FL USA

Oregon Health and Science University Portland OR USA

Royal Adelaide Hospital North Terrace Australia

Seoul St Mary's Hospital South Korea

Seràgnoli Institute of Hematology Department of Experimental Diagnostic and Specialty Medicine University of Bologna Italy

St Vincent's Hospital University of Melbourne Australia

Ulsan University Hospital South Korea

Unite de Genomique du Myelome CHU Rangueil Toulouse France

Universitaetsklinikum Tuebingen der Eberhard Karls Universitaet Abteilung fuer Innere Medizin 2 Tübingen Germany

University Hospital of Salamanca IBSAL Spain

Winship Cancer Institute Emory University Atlanta GA USA

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045233
003      
CZ-PrNML
005      
20200526102119.0
007      
ta
008      
200109s2018 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2018.194118 $2 doi
035    __
$a (PubMed)30237264
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Spencer, Andrew $u Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia aspencer@netspace.net.au.
245    10
$a Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR / $c A. Spencer, S. Lentzsch, K. Weisel, H. Avet-Loiseau, TM. Mark, I. Spicka, T. Masszi, B. Lauri, MD. Levin, A. Bosi, V. Hungria, M. Cavo, JJ. Lee, AK. Nooka, H. Quach, C. Lee, W. Barreto, P. Corradini, CK. Min, EC. Scott, AA. Chanan-Khan, N. Horvath, M. Capra, M. Beksac, R. Ovilla, JC. Jo, HJ. Shin, P. Sonneveld, D. Soong, T. Casneuf, C. Chiu, H. Amin, M. Qi, P. Thiyagarajah, AK. Sasser, JM. Schecter, MV. Mateos,
520    9_
$a Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or refractory multiple myeloma. A post hoc analysis based on treatment history and longer follow up is presented. After 19.4 (range: 0-27.7) months of median follow up, daratumumab plus bortezomib and dexamethasone prolonged progression-free survival (median: 16.7 versus 7.1 months; hazard ratio, 0.31; 95% confidence interval, 0.24-0.39; P<0.0001) and improved the overall response rate (83.8% versus 63.2%; P<0.0001) compared with bortezomib and dexamethasone alone. The progression-free survival benefit of daratumumab plus bortezomib and dexamethasone was most apparent in patients with 1 prior line of therapy (median: not reached versus 7.9 months; hazard ratio, 0.19; 95% con fidence interval, 0.12-0.29; P<0.0001). Daratumumab plus bortezomib and dexamethasone was also superior to bortezomib and dexamethasone alone in subgroups based on prior treatment exposure (bortezomib, thalidomide, or lenalidomide), lenalidomide-refractory status, time since last therapy (≤12, >12, ≤6, or >6 months), or cytogenetic risk. Minimal residual disease-negative rates were >2.5-fold higher with daratumumab across subgroups. The safety profile of daratumumab plus bortezomib and dexamethasone remained consistent with longer follow up. Daratumumab plus bortezomib and dexamethasone demonstrated significant clinical activity across clinically relevant subgroups and provided the greatest benefit to patients treated at first relapse. Trial registration: clinicaltrials.gov identifier: 02136134.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a monoklonální protilátky $x aplikace a dávkování $7 D000911
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a bortezomib $x aplikace a dávkování $7 D000069286
650    _2
$a dexamethason $x aplikace a dávkování $7 D003907
650    _2
$a chemorezistence $7 D019008
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x farmakoterapie $x patologie $7 D009101
650    _2
$a lokální recidiva nádoru $7 D009364
650    _2
$a reziduální nádor $x diagnóza $7 D018365
650    _2
$a hodnocení výsledků zdravotní péče $x metody $x statistika a číselné údaje $7 D017063
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lentzsch, Suzanne $u Division of Hematology/Oncology, Columbia University, New York, NY, USA.
700    1_
$a Weisel, Katja $u Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, Tübingen, Germany.
700    1_
$a Avet-Loiseau, Hervé $u Unite de Genomique du Myelome, CHU Rangueil, Toulouse, France.
700    1_
$a Mark, Tomer M $u Department of Medicine, University of Colorado, Aurora, CO, USA.
700    1_
$a Spicka, Ivan $u Clinical Department of Haematology, 1 Medical Department, Charles University in Prague, Czech Republic.
700    1_
$a Masszi, Tamas $u Department of Haematology and Stem Cell Transplantation, St László Hospital, 3 Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
700    1_
$a Lauri, Birgitta $u Department of Hematology, Sunderbyn Hospital, Luleå, Sweden.
700    1_
$a Levin, Mark-David $u Albert Schweitzer Hospital Department of Internal Medicine, Dordrecht, the Netherlands.
700    1_
$a Bosi, Alberto $u Department of Hematology, Careggi Hospital and University of Florence, Italy.
700    1_
$a Hungria, Vania $u Irmandade Da Santa Casa De Misericordia De São Paulo, Brazil.
700    1_
$a Cavo, Michele $u "Seràgnoli" Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy.
700    1_
$a Lee, Je-Jung $u Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea.
700    1_
$a Nooka, Ajay K $u Winship Cancer Institute, Emory University, Atlanta, GA, USA.
700    1_
$a Quach, Hang $u St. Vincent's Hospital, University of Melbourne, Australia.
700    1_
$a Lee, Cindy $u Royal Adelaide Hospital, North Terrace, Australia.
700    1_
$a Barreto, Wolney $u Hospital Santa Marcelina, São Paulo, Brazil.
700    1_
$a Corradini, Paolo $u Fondazione IRCCS Instituto Nazionale dei Tumori, University of Milan, Italy.
700    1_
$a Min, Chang-Ki $u Seoul St. Mary's Hospital, South Korea.
700    1_
$a Scott, Emma C $u Oregon Health & Science University, Portland, OR, USA.
700    1_
$a Chanan-Khan, Asher A $u Mayo Clinic Florida, Jacksonville, FL, USA.
700    1_
$a Horvath, Noemi $u Royal Adelaide Hospital, North Terrace, Australia.
700    1_
$a Capra, Marcelo $u Instituto do Cancer-Hospital Mae de Deus, Porto Alegre, Brazil.
700    1_
$a Beksac, Meral $u Ankara University, Turkey.
700    1_
$a Ovilla, Roberto $u Hospital Angeles Lomas, Naucalpan de Juárez y alrededores, México.
700    1_
$a Jo, Jae-Cheol $u Ulsan University Hospital, South Korea.
700    1_
$a Shin, Ho-Jin $u Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, South Korea.
700    1_
$a Sonneveld, Pieter $u Erasmus Medical Center, Rotterdam, the Netherlands.
700    1_
$a Soong, David $u Janssen Research & Development, LLC, Spring House, PA, USA.
700    1_
$a Casneuf, Tineke $u Janssen Research & Development, Beerse, Belgium.
700    1_
$a Chiu, Christopher $u Janssen Research & Development, LLC, Spring House, PA, USA.
700    1_
$a Amin, Himal $u Janssen Research & Development, LLC, Raritan, NJ, USA.
700    1_
$a Qi, Ming $u Janssen Research & Development, LLC, Spring House, PA, USA.
700    1_
$a Thiyagarajah, Piruntha $u Janssen Research & Development, High Wycombe, UK.
700    1_
$a Sasser, A Kate $u Genmab US, Inc, Princeton, NJ, USA.
700    1_
$a Schecter, Jordan M $u Janssen Research & Development, LLC, Raritan, NJ, USA.
700    1_
$a Mateos, Maria-Victoria $u University Hospital of Salamanca/IBSAL, Spain.
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 103, č. 12 (2018), s. 2079-2087
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30237264 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200526102115 $b ABA008
999    __
$a ok $b bmc $g 1483502 $s 1083906
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 103 $c 12 $d 2079-2087 $e 20180920 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Možnosti archivace